Compare HTHT & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTHT | RDY |
|---|---|---|
| Founded | 2005 | 1984 |
| Country | China | India |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 11.9B |
| IPO Year | 2010 | 2001 |
| Metric | HTHT | RDY |
|---|---|---|
| Price | $42.45 | $15.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $56.60 | $16.90 |
| AVG Volume (30 Days) | ★ 2.4M | 1.9M |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.07% | 0.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.18 | $7.72 |
| Revenue Next Year | $6.71 | $3.50 |
| P/E Ratio | $30.34 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.42 | $12.19 |
| 52 Week High | $56.53 | $15.27 |
| Indicator | HTHT | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 36.46 | 78.69 |
| Support Level | $42.07 | $13.80 |
| Resistance Level | $45.65 | N/A |
| Average True Range (ATR) | 1.26 | 0.29 |
| MACD | -0.07 | 0.23 |
| Stochastic Oscillator | 31.81 | 85.91 |
H World Group Ltd a foremost, fast-growing multi-brand hotel group with international operations. The principal business activities of the Company are to develop and operate leased and owned, manachised and franchised hotels mainly in the PRC or PRC Mainland. The Group has two operating segments which are legacy Huazhu and legacy DH according to the way management intends to evaluate results and allocate resources within the Group. The majority of revenue comes from legacy Huazhu. The company has presence in Greater China and also Outside Greater China.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.